INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the closing of its public offering of 4,147,358 shares of
View HTML
Toggle Summary Atara Bio Announces Pricing of Its $65.5 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of
View HTML
Toggle Summary Atara Bio Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of
View HTML
Toggle Summary Atara to Present at the J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that Isaac Ciechanover, M.D., the company's Chief Executive
View HTML
Toggle Summary Atara Biotherapeutics Announces Third Quarter 2014 Operating Results
BRISBANE, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today reported financial results for the third quarter and nine months ended September
View HTML
Toggle Summary Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
BRISBANE, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer
View HTML
Toggle Summary Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
BRISBANE, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin
View HTML
Toggle Summary Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock
View HTML
Toggle Summary Atara Biotherapeutics Announces Immunotherapy Alliance with Memorial Sloan Kettering Cancer Center
– T-cell Technology Harnesses Immune System to Fight Cancer and Infectious Disease –
View HTML
Toggle Summary Atara Biotherapeutics Strengthens Board; Senior Management Team
– Matthew K. Fust joins Board of Directors – – Mitchall G. Clark named Chief Regulatory and Quality Assurance Officer –
View HTML